Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Miricorilant - Corcept Therapeutics

Next Previous
Drug Profile

Miricorilant - Corcept Therapeutics

Alternative Names: CORT-118335

Latest Information Update: 06 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corcept Therapeutics
  • Class Cyclohexanes; Fluorinated hydrocarbons; Hepatoprotectants; Ketones; Pyrimidines; Small molecules
  • Mechanism of Action Glucocorticoid receptor antagonists; Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholism; Non-alcoholic steatohepatitis; Weight gain
  • No development reported Metabolic disorders; Non-alcoholic fatty liver disease

Most Recent Events

  • 27 Apr 2025 Corcept Therapeutics plans to initiate a phase I trial for Hepatic-fibrosis and Non-alcoholic-steatohepatitis in the US (PO) (NCT06947304)
  • 13 Sep 2024 Corcept Therapeutics completes a phase I pharmacokinetic trial for Non-alcoholic Steatohepatitis in USA (NCT05553470)
  • 05 Jun 2024 Pharmacokinetics data from a phase I pharmacokinetics trial in Non-alcoholic Steatohepatitis presented at the European Association for the Study of the Liver Congress 2024 (EASL-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top